Episode #107
How Long Tirzepatide Stays in Your Body (Half-Life Explained) | Mounjaro/Zepbound Guide
#Tirzepatide #Mounjaro #Zepbound #GLP1 #WeightLoss How long does tirzepatide (Mounjaro, Zepbound) actually stay in your system? It's not 5 days. In this video, I explain tirzepatide's half-life using 4 clocks it sets in your body. Those clocks explain when side effects hit and what to do if you miss a dose. They also explain why a 1-week pause before surgery may not be enough, why the birth control rule is 4 weeks, and how long the drug takes to clear after your last shot. Then we get to the clock that matters most: what happens after you stop. You'll see what the SURMOUNT-4 trial found about weight regain and why muscle loss is the real risk. I'll also share how I regained 45 pounds when my own structure disappeared, and the 2 paths that protect your results. FREE GLP-1 Diet Cookbook + Weekly Newsletter Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity. https://www.drmohammedpaika.com/newsletter Complete GLP-1 Weight Loss Masterclass — Lifetime Access Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost. https://www.drmohammedpaika.com TIMESTAMPS 00:00 Why "it's gone in 5 days" is wrong 01:26 What tirzepatide is and how it works 02:25 Half-life explained 02:59 Why it lasts so long: albumin binding 03:48 Clock 1: the 7-day clock 04:18 Side effects: when they hit and how to ease them 05:47 Why food noise returns at the end of the week 06:14 Missed a dose? The 96-hour rule 07:16 Clock 2: the 4-week clock and steady state 08:06 Why your dose goes up in 2.5 mg steps 09:05 Birth control: the 4-week rule 10:09 Clock 3: how long tirzepatide stays in your system 10:56 What makes clearance faster or slower 12:39 Why severe side effects don't stop when you stop 13:42 Surgery, colonoscopy and sedation 15:07 Pregnancy planning 15:35 Will it show up on a drug test? 16:12 Clock 4: what happens when you stop 16:46 Why your body fights weight loss 17:36 SURMOUNT-4: stopping vs staying on 17:58 My own weight-regain story 18:48 The muscle problem 19:51 The plan: 2 good paths 21:17 Protecting your muscle on GLP-1s REFERENCES Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdf Kindel TL, et al. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. 2024. https://www.cghjournal.org/article/S1542-3565(24)00910-8/fulltext American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936 Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. https://pubmed.ncbi.nlm.nih.gov/22029981/ Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. 2022. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36:761–765. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612–1619. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538 Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/ Paika MK. GLP-1 Masterclass; The Weight Equation; Obesity Medicine in Clinical Practice: High-Yield Guide; The Physician's Physique. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
